Source: Eur Respir J 2001; 17: 660-666
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Laudanski J., Niklinska W., Burzykowski T., Chyczewski L., Niklinski J.. Prognostic significance of p53 and bcl-2 abnormalities in operable non-small cell lung cancer. Eur Respir J 2001; 17: 660-666

Member's Comments

No comment yet.

Related content which might interest you: p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Nuclear survivin in pN2 nonsmall cell lung cancer: prognostic and clinical implications Source: Eur Respir J 2009; 33: 127-133 Year: 2009 The association of p53 and p21 expression with clinicopathological parameters and prognosis in non-small cell lung cancer Source: Annual Congress 2010 - Prognostic factors for lung cancer Year: 2010 Prognostic value of p21 protein expression in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 674s Year: 2004 p-53 and HER2/neu expression in relation to chemotherapy response in patients with non-small cell lung cancer Source: Annual Congress 2007 - Novel genetic markers in pathology Year: 2007 Prognostic value of ERCC1 expression in advanced non-small cell lung cancer (NSCLC) Source: Annual Congress 2012 - Prognosis of lung cancer Year: 2012 Prognostic significance of Nestin in resected non-small cell lung cancer Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 The prognostic value of altered pRb and p53 protein expression in non-small cell lung cancer Source: Eur Respir J 2003; 22: Suppl. 45, 363s Year: 2003 HER-2/neu oncoprotein expression in nonsmall cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Expression of Her-2/neu and Bcl-2 in patients with non-small cell lung cancer Source: International Congress 2017 – Gene signatures in bronchial diseases Year: 2017 BAX and p16INK4A are independent positive prognostic markers for advanced tumour stage of nonsmall cell lung cancer Source: Eur Respir J 2002; 19: 134-140 Year: 2002 MDM-2 gene amplification is associated with poor prognosis in operable non-small cell lung cancer (NSCLC) Source: Eur Respir J 2002; 20: Suppl. 38, 596s Year: 2002 Prognostic significance of S-100 immmunostaining in non-small cell lung cancer (NSCLC) Source: Annual Congress 2004 - Prognostic factors Year: 2004 Her/2 neu and p53 expression in patients with non-small cell lung cancer predict shortened survival Source: Annual Congress 2010 - Biomarkers for lung cancer Year: 2010 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Ki-67 in non-small cell lung cancer Source: Annual Congress 2012 - New results in molecular pathology and functional genomics of neoplastic and non-neoplastic lung disease Year: 2012 Survivin expression in non-small cell lung cancer Source: Annual Congress 2010 - Recent developments of molecular pathology and functional genomics in non-neoplastic and neoplastic lung diseases Year: 2010 Expression of Fhit protein in non-small cell lung cancer (NSCLC) and its correlation with Ki-67, a proliferative marker Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Bcl-2 as a prognostic factor for survival in small-cell lung cancer Source: Annual Congress 2009 - Treatment of lung cancer Year: 2009 TNFα as a prognostic factor in surgically treated non-small cell lung carcinomas Source: Annual Congress 2005 - Management of lung cancer: clinical problems Year: 2005